

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Rekha Bansal
Filing Date : October 19, 2003
For : METHOD OF INHIBITING FACTOR
B-MEDIATED COMPLEMENT
ACTIVATION, AND THE USES
THEREOF
Art Unit : 1644
Examiner : Francois P. Vandervegt
Attorney Docket No. : NMT-8440

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This information disclosure statement is being filed to fulfill the duty of candor
and good faith toward the Patent and Trademark Office in accordance with 37 CFR
§1.56.

A copy of the PTO Form 1449 has been attached.

NON-PATENT LITERATURE

Acioli, J.M., M. Isobe, and S. Kawasaki, "Early Complement System Activation and Neutrophil priming in acute pancreatitis: Participation of trypsin", *Surgery* 1997. 122(5) pp. 909-917

Arnaout, M.A., "Structure and function of the leukocyte adhesion molecules CD11/CD18". *Blood*, 1990. 75(5): p. 1037-50

Barnum, S.R., et al., "Expression of the complement C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma". *Am J Respir Crit Care Med*, 2001. 164(10 Pt 1): 1841-3.

Basta, M., I. Illia, and M.C. Dalakas, "Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis". *J Neuroimmunol*, 1996. 71(1-2): p. 227-9.

Bellander, B.M., et al., "Complement activation in the human brain after traumatic head injury". *J Neurotrauma*, 2001. 18(12): p. 1295-311.

Belmont, H.M., et al., "Complement activation during systematic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. *Arthritis Rheum*, 1986. 29(9): p. 1085-9.

Bonser, R.S., et al., "Complement activation before, during and after cardiopulmonary bypass". *Eur J Cardiothorac Surg*, 1990. 4(6): p. 291-6

Chenoweth, D.E., "Anaphylatoxin formation in extracorporeal circuits", *Complement*, 1986. 3(3): p. 152-65.

Davis, E.A., et al., "Inhibition of neutrophil adhesion and the membrane attack complex of complement synergistically prolongs cardiac xenograft survival", *J Heart Lung Transplant*, 1995. 14(5): p. 973-80.

del Balzo, U., M.J. Polley, and R. Levi, "Cardiac anaphylaxis. Complement activation as an amplification system". *Circ Res*, 1989. 65(3):p.847-57.

Fung, M., et al., *Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits*. *J Thorac Cardiovasc Surg*, 2001. 122(1): p. 113-22.

Furman, M.I., et al., *Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction*. *J Am Coll Cardiol*, 2001. 38(4): p. 1002-6.

Furman, M.I., et al., *Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease*. *J Am Coll Cardiol*, 1998. 31(2): p. 352-8.

Gerard, N.P. and C. Gerard, *Complement in allergy and asthma*. *Curr Opin Immunol*, 2002. 14(6): p. 705-8.

Gillinov, A.M., et al., *Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass*. *Ann Thorac Surg*, 1993. 55(3): p. 619-24.

Gloor, B., et al., *Predictive value of complement activation fragments C3a and sC5b-9 for development of severe disease in patients with acute pancreatitis*. Scand J Gastroenterol, 2003. **38**(10): p. 1078-82.

Gong, J., et al., *Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model*. J Clin Immunol, 1996. **16**(4): p. 222-9.

Grant, E.P., et al., *Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis*. J Exp Med, 2002. **196**(11): p. 1461-71.

Grossklaus, C., et al., *Induction of platelet aggregation by the complement-derived peptides C3a and C5a*. Naunyn Schmiedebergs Arch Pharmacol, 1976. **295**(1): p. 71-6.

Gupta-Bansal, R., J.B. Parent, and K.R. Brunden, *Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies*. Mol Immunol, 2000. **37**(5): p. 191-201.

Haeffner-Cavaillon, N., et al., *C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes*. J Immunol, 1987. **139**(3): p. 794-9.
Halstensen TS, Brandtzaeg P., *Local Complement activation in inflammatory bowel disease*, Immunol Res. 1991; 10(3-4): 485-92.

Holmes, J.H.t., et al., *Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes*. Inflamm Res, 2002. **51**(12): p. 579-86.

Hopkins, P., et al., *Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis*. Arthritis Rheum, 1988. **31**(5): p. 632-41.

Horigome, I., et al., *Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases*. Clin Exp Immunol, 1987. **70**(2): p. 417-24.

Howard, R.J., et al., *Effects of cardiopulmonary bypass on pulmonary leukostasis and complement activation*. Arch Surg, 1988. **123**(12): p. 1496-501.

Humbles, A.A., et al., *A role for the C3a anaphylatoxin receptor in the effector phase of asthma*. Nature, 2000. **406**(6799): p. 998-1001.

Johnson, L.V., et al., *Complement activation and inflammatory processes in Drusen formation and age related macular degeneration*. Exp Eye Res, 2001. **73**(6): p. 887-96.

Kaczorowski, S.L., et al., *Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats*. J Cereb Blood Flow Metab, 1995. **15**(5): p. 860-4.

Kirschfink, M., et al., *[Significance of the complement system for xenotransplantation: strategies for therapeutic intervention]*. Zentralbl Chir, 1998. **123**(7): p. 793-7.

Krug, N., et al., *Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma*. Am J Respir Crit Care Med, 2001. **164**(10 Pt 1): p. 1841-3.

Langlois, P.F. and M.S. Gawryl, *Detection of the terminal complement complex in patient plasma following acute myocardial infarction*. Atherosclerosis, 1988. **70**(1-2): p. 95-105.

Lien, Y.H., L.W. Lai, and A.L. Silva, *Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice*. Life Sci, 2003. **74**(5): p. 543-52.

Lin F. et al., *Decay-Accelerating Factor Deficiency Increases Susceptibility to Dextran Sulfate Sodium-Induced Colitis: Role for Complement in Inflammatory Bowel Disease*, Journal of Immunology 2004, 172:3836-3841

Mead, R.J., et al., *The membrane attack complex of complement causes severe demyelination associated with acute axonal injury*. J Immunol, 2002. **168**(1): p. 458-65.

Meuer, S., et al., *Platelet-serotonin release by C3a and C5a: two independent pathways of activation*. J Immunol, 1981. **126**(4): p. 1506-9.

Mohr, R., et al., *The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations*. J Thorac Cardiovasc Surg, 1988. **96**(4): p. 530-4.

Mullins, R.F., N. Aptsiauri, and G.S. Hageman, *Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis*. Eye, 2001. **15**(Pt 3): p. 390-5.

Nataf, S., et al., *Attenuation of experimental autoimmune demyelination in complement-deficient mice*. J Immunol, 2000. **165**(10): p. 5867-73.

Pruitt, S.K., et al., *The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts*. Transplantation, 1994. **57**(3): p. 363-70.

Rinder, C.S., et al., *Cardiopulmonary bypass induces leukocyte-platelet adhesion*. Blood, 1992. **79**(5): p. 1201-5.

Rinder, C.S., et al., *Role of C3 cleavage in monocyte activation during extracorporeal circulation*. Circulation, 1999. **100**(5): p. 553-8.

Rinder, C.S., et al., *Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation*. J Clin Invest, 1995. **96**(3): p. 1564-72.

Roxvall, L., A. Bengtson, and M. Heideman, *Anaphylatoxin generation in acute pancreatitis*. J Surg Res, 1989. **47**(2): p. 138-43.

Roxvall, L.I., L.A. Bengtson, and J.M. Heideman, *Anaphylatoxins and terminal complement complexes in pancreatitis. Evidence of complement activation in plasma and ascites fluid of patients with acute pancreatitis*. Arch Surg, 1990. **125**(7): p. 918-21.

Saatvedt, K., et al., *Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children*. Scand J Clin Lab Invest, 1995. **55**(1): p. 79-86.

Schmid, E., et al., *Requirement for C5a in lung vascular injury following thermal trauma to rat skin*. Shock, 1997. **8**(2): p. 119-24.

Simpson, P.J., et al., *Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion*. J Clin Invest, 1988. **81**(2): p. 624-9.

Stahel, P.F., M.C. Morganti-Kossmann, and T. Kossmann, *The role of the complement system in traumatic brain injury*. Brain Res Brain Res Rev, 1998. **27**(3): p. 243-56.

Stahl, G.L., et al., *Role for the alternative complement pathway in ischemia/reperfusion injury*. Am J Pathol, 2003. **162**(2): p. 449-55.

Thurman, J.M., et al., *Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice*. J Immunol, 2003. **170**(3): p. 1517-23.

Torzewski, J., et al., *Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation*. Arterioscler Thromb Vasc Biol, 1996. **16**(5): p. 673-7.

Undar, A., et al., *Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass*. Ann Thorac Surg, 2002. **74**(2): p. 355-62; discussion 362.

van Beek, J., K. Elward, and P. Gasque, *Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection*. Ann N Y Acad Sci, 2003. **992**: p. 56-71.

Vedeler, C.A., et al., *Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barre syndrome and multiple sclerosis*. J Neuroimmunol, 1996. **67**(1): p. 17-20.

Vickers, J., et al., *Measurement of platelet activation and adhesion to leukocytes during haemodialysis*. Platelets, 1998. **9**(3-4): p. 261-4.

Wan, K.C., et al., *A longitudinal study of C3, C3d and factor Ba in burn patients in Hong Kong Chinese*. Burns, 1998. **24**(3): p. 241-4.

Wang, Y., et al., *Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease*. Proc Natl Acad Sci U S A, 1995. **92**(19): p. 8955-9.

Ware, L.B. and M.A. Matthay, *The acute respiratory distress syndrome*. N Engl J Med, 2000. **342**(18): p. 1334-49.

Yasuda, M., et al., *The complement system in ischemic heart disease*. Circulation, 1990. **81**(1): p. 156-63.

Zhou, W., et al., *Predominant role for C5b-9 in renal ischemia/reperfusion injury*. J Clin Invest, 2000. **105**(10): p. 1363-71.

Ahlgren, E., et al., *Neurocognitive impairment and driving performance after coronary artery bypass surgery*. Eur J Cardiothorac Surg, 2003. **23**(3): p. 334-40.

Ann Thorac Surg. 1994 Mar;57(3):781-3, P.C.a.a.C.a.c.d.c.b.M.P., Chello M, Marchese AR.).

Arrowsmith, J.E., et al., *Central nervous system complications of cardiac surgery*. Br J Anaesth, 2000. **84**(3): p. 378-93.

Cecic, I., J. Sun, and M. Korbelik, *Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells*. Photochem Photobiol, 2006. **82**(2): p. 558-62.

Keith, J.R., et al., *Assessing postoperative cognitive change after cardiopulmonary bypass surgery*. Neuropsychology, 2002. **16**(3): p. 411-21.

Larsson, R., et al., *Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface*. Immunopharmacology, 1997. **38**(1-2): p. 119-27.

Levy, J.H. and K.A. Tanaka, *Inflammatory response to cardiopulmonary bypass*. Ann Thorac Surg, 2003. **75**(2): p. S715-20.

Mahanna, E.P., et al., *Defining neuropsychological dysfunction after coronary artery bypass grafting*. Ann Thorac Surg, 1996. **61**(5): p. 1342-7.

Neumann, E., et al., *Local production of complement proteins in rheumatoid arthritis synovium*. Arthritis Rheum, 2002. **46**(4): p. 934-45.

Newman, M.F., Kirchner J.L., Phillips-Bute B., *Longitudinal assessment of neurocognitive function after coronary artery bypass surgery*. N Engl J Med, 2001. **344**: p. 395-402.

Nilsson B, L.R., Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD., Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation., Blood. 1998 Sep 1;92(5):1661-7.

Rinder, C.S., et al., *Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation*. J Thorac Cardiovasc Surg, 1999. **118**(3): p. 460-6.

Selnes, O.A. and G.M. McKhann, *Neurocognitive complications after coronary artery bypass surgery*. Ann Neurol, 2005. **57**(5): p. 615-21.

Selnes, O.A., et al., *Cognitive and neurobehavioral dysfunction after cardiac bypass procedures*. Neurol Clin, 2006. **24**(1): p. 133-45.

Respectfully submitted,

/Richard A. Sutkus/
Richard A. Sutkus
Reg. No. 43,941

TAROLLI, SUNDHEIM, COVELL,
& TUMMINO L.L.P.
1300 East Ninth Street, Suite 1700
Cleveland, Ohio 44114
Phone:(216) 621-2234
Fax: (216) 621-4072
Customer No.: 26,294